Concepedia

Amy Prawira

AP

Statistics

Publications

16

Citations

960

H-Index

13

Active since

2014

Affiliations

Princess Margaret Cancer Centre(Current)

University Health Network

University of Toronto

St Vincent's Hospital Sydney

The University of Texas MD Anderson Cancer Center

Amy Prawira is an author at Princess Margaret Cancer Centre specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2014–2022

16

Publications

16

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Janice M. Mehnert, Andréa Varga, Marcia S. Brose et al. · BMC Cancer · 2019 · 221 citations · Full text

, , +17

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 156 citations · Full text

, , +17

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Charu Aggarwal, Amy Prawira, Scott Antonia et al. · Journal for ImmunoTherapy of Cancer · 2022 · 141 citations · Full text

, , +17

Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.

David S. Hong, Patrick Schöffski, Aitana Calvo et al. · Journal of Clinical Oncology · 2018 · 70 citations

, , +17

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Johanna C. Bendell, Philippe L. Bédard, Yung‐Jue Bang et al. · Cancer Research · 2020 · 64 citations

, , +17

1–5 of 16